Grace Therapeutics Q2 2027 net loss more than doubles to $2.1 million

• Grace Therapeutics’ net loss more than doubled to $2.1 million in the three months ended September 30, 2026.
• Research and development expenses rose 50% to $900,000, while general and administrative expenses fell 30% to $1.4 million from a year earlier.
• Cash and cash equivalents totaled $21.3 million at September 30, 2026, with planned operations funded through the end of calendar 2028.
• The FDA identified no clinical safety or efficacy deficiencies in its GTx-104 complete response letter and requested no additional clinical data.
• A dual-source manufacturing strategy is progressing, with GTx-104 application resubmission timing dependent on which manufacturing site reaches readiness first.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-043308), on November 12, 2026, and is solely responsible for the information contained therein.